Cingulate

Cingulate Equity

The The Equity of Cingulate (CING) as of Nov 11, 2026 is 2.51 M USD. In the previous year, The Equity was 7.46 M USD — a change of -66.35% (lower).

Equity

2.51 MUSD

YoY

-66.35%

Last updated:

In 2025, Cingulate's equity was 2.51 M USD, a -66.35% increase from the 7.46 M USD equity in the previous year.

The Cingulate Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2019
615,880.00 USD
Jan 1, 2020
1.29 M USD
Jan 1, 2021
20.84 M USD
Jan 1, 2022
3.88 M USD
Jan 1, 2023
-6.87 M USD
Jan 1, 2024
7.46 M USD
Jan 1, 2025
2.51 M USD
The Cingulate Equity history
YEAREquityYoY
2.51 MUSD-66.35%
7.46 MUSD-208.53%
-6.87 MUSD-276.95%
3.88 MUSD-81.38%
20.84 MUSD+1,512.73%
1.29 MUSD+109.85%
615,880.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cingulate Stock analysis

What does Cingulate do? Cingulate Inc is a US-based biopharmaceutical company headquartered in Kansas City, Kansas, that focuses on the development, manufacturing, and commercialization of pharmaceutical products. The firm utilizes its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles designed to improve the lives of patients suffering from commonly diagnosed conditions. The company specifically targets the treatment of attention deficit/hyperactivity disorder (ADHD) through its innovative approach to drug delivery. The firm is currently developing two lead product candidates, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). These drug candidates both contain three releases of an active pharmaceutical ingredient combined into one small tablet dosage form. By employing this technology, Cingulate Inc aims to provide effective treatment options for ADHD across three core patient segments: children aged 6-12, adolescents aged 13-17, and adults aged 18 and older. Cingulate is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Cingulate's Equity

Cingulate's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Cingulate's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Cingulate's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Cingulate's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Cingulate’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Cingulate stock

The Equity of Cingulate is 2.51 M USD in 2025.

The Equity of Cingulate changed from 7.46 M USD to 2.51 M USD, representing a -66.35% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Cingulate since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Cingulate historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Cingulate

All Key Metrics — Cingulate